Skip to main content
SpringerLink
Log in

Outpatient Medications in Atrial Fibrillation

  • Chapter
  • First Online:
Short Stay Management of Atrial Fibrillation

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 972 Accesses

Abstract

The three outpatient principles for managing patients with atrial fibrillation are (1) risk stratification and appropriate stroke prevention, (2) rate control to prevent symptomatic tachycardia and tachycardia-induced cardiomyopathy, and (3) rhythm control for patients who have symptomatic atrial fibrillation despite rate control. In this chapter, we will focus on the outpatient use of medications for rate and rhythm control.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wyse D, Waldo A, DiMarco J, Domanski M, Rosenberg Y, Schron E, Kellen J, Greene H, Mickel M, Dalquist J. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825.

    Article  CAS  PubMed  Google Scholar 

  2. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJM, Tijssen JGP. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Eng JMed. 2002;347(23):1834–40.

    Article  Google Scholar 

  3. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL, Atrial F Congestive Heart Failure I. .Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–77.

    Article  CAS  PubMed  Google Scholar 

  4. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36(1):122–33.

    Article  PubMed  Google Scholar 

  5. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis Jr HD, Raisch DW, Ezekowitz MD. Sotalol Amiodarone Atrial Fibrillation Efficacy Trial I. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352(18):1861–72.

    Article  CAS  PubMed  Google Scholar 

  6. Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma JH, Crijns HJ, Van Gelder IC, Group RS. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol. 2004;43(2):241–7.

    Article  PubMed  Google Scholar 

  7. Hohnloser SH, Kuck K-H, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. The Lancet. 2000;356(9244):1789–94.

    Article  CAS  Google Scholar 

  8. Ha AC, Breithardt G, Camm AJ, Crijns HJ, Fitzmaurice GM, Kowey PR, Le Heuzey JY, Naditch-Brule L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub WS, Dorian P. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes. 2014;7(6):896–904.

    Article  PubMed  Google Scholar 

  9. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.

    Article  PubMed  Google Scholar 

  10. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, American College of Cardiology/American Heart Association Task Force on Practice G. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.

    Article  PubMed  Google Scholar 

  11. Toivonen L, Kadish A, Kou W, Morady F. Determinants of the ventricular rate during atrial fibrillation. J Am Coll Cardiol. 1990;16(5):1194–200.

    Article  CAS  PubMed  Google Scholar 

  12. Kawakubo K, Murayama M, Itai T, Ono S, Musha H, Ito H, Arai S. Heart rate at onset and termination of paroxysmal atrial fibrillation in apparently healthy subjects. Jpn Heart J. 1986;27(5):645–51.

    Article  CAS  PubMed  Google Scholar 

  13. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29(4):709–15.

    Article  CAS  PubMed  Google Scholar 

  14. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP, Investigators RI. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363–73.

    Article  PubMed  Google Scholar 

  15. Tenormin (atenolol) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018240s031lbl.pdf. Revised July 2011. Accessed 29 May 2015.

  16. Zebeta (bisoprolol fumarate) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf. Revised May 2007. Accessed 29 May 2015.

  17. Coreg (carvedilol) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020297s029lbl.pdf. Revised December 2008. Accessed 29 May 2015.

  18. Coreg CR (carvedilol phosphate) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022012s010s013lbl.pdf. Revised December 2008. Accessed 29 May 2015.

  19. Lopressor (metoprolol tartrate) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017963s062,018704s021lbl.pdf. Revised February 2008. Accessed 29 May 2015.

  20. Toprol XL (metoprolol succinate) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019962s032lbl.pdf. Revised March 2006. Accessed 29 May 2015.

  21. Corgard (nadolol) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018063s060lbl.pdf. Revised July 2007. Accessed 29 May 2015.

  22. Inderal (propranolol hydrochloride) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf. Revised November 2010. Accessed 29 May 2015.

  23. Calan (verapamil hydrochloride) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018817s021lbl.pdf. Revised May 2009. Accessed 29 May 2015.

  24. Cardizem (diltiazem hydrochloride) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018602s063lbl.pdf. Revised November 2009. Accessed 29 May 2015.

  25. Cardizem LA (diltiazem hydrochloride extended release) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021392s014lbl.pdf. Revised November 2010. Accessed 29 May 2015.

  26. Lanoxin (digoxin) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020405s006lbl.pdf. Revised November 2011. Accessed 29 May 2015.

  27. Cordarone (amiodarone hydrochloride) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf. Accessed 29 May 2015.

  28. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O’Neill G, Sharma A, Platia E, Feld GK, Akiyama T, Brodsky MA, Greene HL, Investigators A. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201–8.

    Article  PubMed  Google Scholar 

  29. Investigators AI, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364(10):928–38.

    Article  Google Scholar 

  30. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  CAS  PubMed  Google Scholar 

  31. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR, Committee RAS, Investigators. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363–70.

    Article  CAS  PubMed  Google Scholar 

  32. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  CAS  PubMed  Google Scholar 

  33. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    Article  CAS  PubMed  Google Scholar 

  34. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP, Investigators O-A. Digoxin use and subsequent outcomes among patients in a contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65(25):2691–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Steinberg BA, Holmes DN, Ezekowitz MD, Fonarow GC, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Chang P, Peterson ED, Piccini JP. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2013;165(4):622–9.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, Schmitt S, Holmes TH, Frayne SM, Phibbs CS, Yang F, Hoang DD, Ho PM, Heidenreich PA. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8(1):49–58.

    Article  CAS  PubMed  Google Scholar 

  38. Piccini JP, Mi X, DeWald TA, Go AS, Hernandez AF, Curtis LH. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012;9(9):1403–8.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hilliard AA, Miller TD, Hodge DO, Gibbons RJ. Heart rate control in patients with atrial fibrillation referred for exercise testing. Am J Cardiol. 2008;102(6):704–8.

    Article  PubMed  Google Scholar 

  40. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33(2):304–10.

    Article  CAS  PubMed  Google Scholar 

  41. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42(11):1944–51.

    Article  CAS  PubMed  Google Scholar 

  42. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, Hamdan MH, Page RL. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142(3):498–501.

    Article  CAS  PubMed  Google Scholar 

  43. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF, Lip GYH, Coats AJS, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. The Lancet. 2014;384(9961):2235–43.

    Article  CAS  Google Scholar 

  44. Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation. 1982;65(2):348–54.

    Article  CAS  PubMed  Google Scholar 

  45. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 1986;73(2):316–24.

    Article  CAS  PubMed  Google Scholar 

  46. Maragno I, Santostasi G, Gaion RM, Trento M, Grion AM, Miraglia G, Dalla VS. Low- and medium-dose diltiazem in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J. 1988;116(2 Pt 1):385–92.

    Article  CAS  PubMed  Google Scholar 

  47. Atwood JE, Myers JN, Sullivan MJ, Forbes SM, Pewen WF, Froelicher VF. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest. 1988;93(1):20–5.

    Article  CAS  PubMed  Google Scholar 

  48. Botto GL, Bonini W, Broffoni T. Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil. Clin Cardiol. 1998;21(11):837–40.

    Article  CAS  PubMed  Google Scholar 

  49. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol. 1990;16(1):86–90.

    Article  CAS  PubMed  Google Scholar 

  50. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Rienstra M, Van den Berg MP, Van Gelder IC, Investigators RI. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014;11(9):1543–50.

    Article  PubMed  Google Scholar 

  51. Digitalis IG. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.

    Article  Google Scholar 

  52. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8.

    Article  CAS  PubMed  Google Scholar 

  53. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, Patel K, Aban IB, Aronow WS, Anker SD, Ahmed A. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34(20):1489–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart. 2008;94(2):191–6.

    Article  CAS  PubMed  Google Scholar 

  55. Tse HF, Lam YM, Lau CP, Cheung BM, Kumana CR. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28(5-6):446–50.

    Article  CAS  PubMed  Google Scholar 

  56. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321(6):406–12.

    Google Scholar 

  57. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327(4):227–33.

    Google Scholar 

  58. Norpace (disopyramide phosphate capsules) Label. NIH Website. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677. Revised February 2010. Accessed 29 May 2015.

  59. Quinidine gluconate extended release label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/089338s036lbl.pdf. Revised August 2009. Accessed 29 May 2015.

  60. Quinidine sulfate Label. NIH Website. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a90a03b0-ffbe-4cf6-90b5-bfb0412a1cb2. Revised June 2009. Accessed 29 May 2015.

  61. Tambocor (flecainide acetate) Label. NIH Website. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b764c8b8-7e23-4016-830f-68312d84f3d3. Revised January 2006. Accessed 29 May 2015.

  62. RHYTHMOL SR (propafenone hydrochloride) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021416s011lbl.pdf. Revised February 2013. Accessed 29 May 2015.

  63. Tikosyn (dofetilide) Label. FDA Website. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM266277.pdf. Revised 2013. Accessed 29 May 2015.

  64. MULTAQ (dronedarone) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf. Revised July 2009. Accessed 29 May 2015.

  65. BETAPACE (sotalol HCl) Label. FDA Website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s019lbl.pdf. Revised October 2010. Accessed 29 May 2015.

  66. Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart. 2000;84(1):37–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett EL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation. 1989;80(6):1557–70.

    Article  CAS  PubMed  Google Scholar 

  68. Chimienti M, Cullen Jr MT, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J. 1995;16(12):1943–51.

    CAS  PubMed  Google Scholar 

  69. Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol. 1996;77(3):66A–71.

    Article  CAS  PubMed  Google Scholar 

  70. Pritchett EL, Page RL. Carlson M, Undesser K, Fava G, Rythmol Atrial Fibrillation Trial I. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003;92(8):941–6.

    Article  CAS  PubMed  Google Scholar 

  71. Meinertz T, Lip GY, Lombardi F, Sadowski ZP, Kalsch B, Camez A, Hewkin A, Eberle S, Investigators E. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol. 2002;90(12):1300–6.

    Article  CAS  PubMed  Google Scholar 

  72. Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, Dabizzi RP. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88(6):640–5.

    Article  CAS  PubMed  Google Scholar 

  73. Kochiadakis GE, Marketou ME, Igoumenidis NE, Chrysostomakis SI, Mavrakis HE, Kaleboubas MD, Vardas PE. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? Pacing Clin Electrophysiol. 2000;23(11 Pt 2):1883–7.

    Article  CAS  PubMed  Google Scholar 

  74. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342(13):913–20.

    Article  CAS  PubMed  Google Scholar 

  75. Kochiadakis GE, Igoumenidis NE, Hamilos MI, Tzerakis PG, Klapsinos NC, Zacharis EA, Vardas PE. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest. 2004;125(2):377–83.

    Article  CAS  PubMed  Google Scholar 

  76. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351(23):2384–91.

    Article  CAS  PubMed  Google Scholar 

  77. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251–8.

    Article  CAS  PubMed  Google Scholar 

  78. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J. 1988;9(3):284–90.

    CAS  PubMed  Google Scholar 

  79. Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther. 1996;10(2):145–52.

    Article  CAS  PubMed  Google Scholar 

  80. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82(4):1106–16.

    Article  CAS  PubMed  Google Scholar 

  81. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82(6):1932–9.

    Article  CAS  PubMed  Google Scholar 

  82. Allen LaPointe NM, Chen A, Hammill B, DeLong E, Kramer JM, Califf RM. Evaluation of the dofetilide risk-management program. Am Heart J. 2003;146(5):894–901.

    Article  CAS  PubMed  Google Scholar 

  83. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing Jr CB. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102(19):2385–90.

    Article  CAS  PubMed  Google Scholar 

  84. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341(12):857–65.

    Article  CAS  PubMed  Google Scholar 

  85. Kober L, Bloch Thomsen PE, Moller M, Torp-Pedersen C, Carlsen J, Sandoe E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ. Danish Investigations of A, Mortality on Dofetilide Study G. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 2000;356(9247):2052–8.

    Article  CAS  PubMed  Google Scholar 

  86. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001;104(3):292–6.

    Article  CAS  PubMed  Google Scholar 

  87. Investigators AFADS. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42(1):20–9.

    Article  Google Scholar 

  88. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13(3):329–45.

    Article  PubMed  Google Scholar 

  89. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54(12):1089–95.

    Article  CAS  PubMed  Google Scholar 

  90. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003;68(11):2189–96.

    PubMed  Google Scholar 

  91. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000;160(12):1741–8.

    Article  CAS  PubMed  Google Scholar 

  92. Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB, Committees A. Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541–50.

    Article  CAS  PubMed  Google Scholar 

  93. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH. Euridis, Investigators A. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987–99.

    Article  CAS  PubMed  Google Scholar 

  94. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ, Investigators A. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668–78.

    Article  CAS  PubMed  Google Scholar 

  95. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J, Dronedarone SG. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–87.

    Article  PubMed  Google Scholar 

  96. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH, Investigators P. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268–76.

    Article  CAS  PubMed  Google Scholar 

  97. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597–605.

    Article  PubMed  Google Scholar 

  98. Laboratories B. Betapace (sotalol hydrochloride) product information. 2004. In. Montville NJ.

    Google Scholar 

  99. Benditt DG, Williams JH, Jin J, Deering TF, Zucker R, Browne K, Chang-Sing P, Singh BN. Maintenance of sinus rhythm with oral d, l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d, l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84(3):270–7.

    Article  CAS  PubMed  Google Scholar 

  100. de Paola AA, Veloso HH. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of Sao Paulo. Am J Cardiol. 1999;84(9):1033–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA

    L. Kristin Newby MD, MHS & Sean D. Pokorney MD, MBA

Authors
  1. L. Kristin Newby MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean D. Pokorney MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Kristin Newby MD, MHS .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Department of Emergency Medicine Baylor College of Medicine, HOUSTON, Texas, USA

    W. Frank Peacock

  2. Department of Emergency Medicine, Beaumont Health System, William Beaumont Hospital, William Beaumont School of Medicine, Oakland University, Royal Oak, Michigan, USA

    Carol L. Clark

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Newby, L.K., Pokorney, S.D. (2016). Outpatient Medications in Atrial Fibrillation. In: Peacock, W., Clark, C. (eds) Short Stay Management of Atrial Fibrillation. Contemporary Cardiology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-31386-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31386-3_18

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-31384-9

  • Online ISBN: 978-3-319-31386-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation